SIAH1/2 Antibody
Cat# MBS8581996-0,1mL-PE
Size : 0.1mL(PE)
Brand : MyBiosource
SIAH1/2 Antibody – Rabbit Polyclonal
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS8581996MBS8581996 is an antibody targeting SIAH1/2. Also known as SIAH1/2 Antibody. Reactive in Human, Mouse, Rat, Chicken, Zebrafish. Host: Rabbit. Rabbit polyclonal antibody to SIAH1/2 More details
Product Overview
Online Datasheet in PDFProduct Name
SIAH1/2, Polyclonal Antibody
Full Product Name
SIAH1/2 Antibody
Product Gene Name
anti-SIAH1/2 antibody
Product Synonym Gene Name
SIAH1, SIAH2
Product Synonym Names
SIAH1; HUMSIAH; E3 ubiquitin-protein ligase SIAH1; Seven in absentia homolog 1; Siah-1; Siah-1a; SIAH2; E3 ubiquitin-protein ligase SIAH2; Seven in absentia homolog 2; Siah-2; hSiah2
Clonality
Polyclonal
Isotype
IgG
Host
Rabbit
Species Reactivity
Human, Mouse, Rat, Chicken, Zebrafish
Form/Format
Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH7.3, 30% glycerol, and 0.01% sodium azide.
Purity/Purification
The antibody was purified by immunogen affinity chromatography.
Specificity
Recognizes endogenous levels of SIAH1/2 protein.
Preparation and Storage
Shipped at 4 degree C. Upon delivery aliquot and store at -20 degree C for one year. Avoid freeze/thaw cycles.
Molecular Weight
282
OMIM
602212
Immunogen
KLH-conjugated synthetic peptide encompassing a sequence within the center region of human SIAH1/2. The exact sequence is proprietary.
Product Categories/Family for anti-SIAH1/2 antibody
Primary Antibody
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Applications Tested/Suitable for anti-SIAH1/2 antibody
Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC)
Application Notes for anti-SIAH1/2 antibody
WB: 1:500-1:1000
IHC: 1:50-1:200
IHC: 1:50-1:200
Other Notes
Small volumes of anti-SIAH1/2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for SIAH1/2. It may not necessarily be applicable to this product.
NCBI Official Full Name
E3 ubiquitin-protein ligase SIAH1
NCBI Official Synonym Full Names
siah E3 ubiquitin protein ligase 1
NCBI Official Symbol
SIAH1
NCBI Official Synonym Symbols
SIAH1A
UniProt Protein Name
E3 ubiquitin-protein ligase SIAH1
UniProt Synonym Protein Names
Seven in absentia homolog 1; Siah-1; Siah-1a
UniProt Gene Name
SIAH1
UniProt Synonym Gene Names
HUMSIAH; Siah-1
UniProt Entry Name
SIAH1_HUMAN
NCBI Protein Information
E3 ubiquitin-protein ligase SIAH1; siah-1a; seven in absentia homolog 1
NCBI Summary for SIAH1/2
This gene encodes a protein that is a member of the seven in absentia homolog (SIAH) family. The protein is an E3 ligase and is involved in ubiquitination and proteasome-mediated degradation of specific proteins. The activity of this ubiquitin ligase has been implicated in the development of certain forms of Parkinson's disease, the regulation of the cellular response to hypoxia and induction of apoptosis. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
Show more UniProt Comments for SIAH1/2
SIAH1: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin- conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Mediates E3 ubiquitin ligase activity either through direct binding to substrates or by functioning as the essential RING domain subunit of larger E3 complexes. Triggers the ubiquitin-mediated degradation of many substrates, including proteins involved in transcription regulation (MYB, POU2AF1, PML and RBBP8), a cell surface receptor (DCC), the cell-surface receptor-type tyrosine kinase FLT3, the cytoplasmic signal transduction molecules (KLF10/TIEG1 and NUMB), an antiapoptotic protein (BAG1), a microtubule motor protein (KIF22), a protein involved in synaptic vesicle function in neurons (SYP), a structural protein (CTNNB1) and SNCAIP. Confers constitutive instability to HIPK2 through proteasomal degradation. It is thereby involved in many cellular processes such as apoptosis, tumor suppression, cell cycle, axon guidance, transcription regulation, spermatogenesis and TNF-alpha signaling. Has some overlapping function with SIAH2. Induces apoptosis in cooperation with PEG3. Upon nitric oxid (NO) generation that follows apoptotic stimulation, interacts with S- nitrosylated GAPDH, mediating the translocation of GAPDH to the nucleus. GAPDH acts as a stabilizer of SIAH1, facilitating the degradation of nuclear proteins. Homodimer. Interacts with group 1 glutamate receptors GRM1 and GRM5. Interacts with DAB1, which may inhibit its activity. Interacts with UBE2E2. Interacts with PEG3. Interacts with GAPDH; leading to stabilize SIAH1. Component of some large E3 complex composed of UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X. Interacts with UBE2I. Interacts with alpha- tubulin. Interacts with PEG10, which may inhibit its activity. Interacts with KHDRBS3. Interacts with SNCAIP and HIPK2. May be induced by p53/TP53, suggesting that it may be required to modulate p53/TP53 response. The relevance of such activity in vivo is however unclear and may not exist. Widely expressed at a low level. Down- regulated in advanced hepatocellular carcinomas. Inhibited by interaction with SNCAIP (isoform 2, but not isoform 1). May be inhibited by interaction with PEG10. Belongs to the SINA (Seven in absentia) family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 6.3.2.-; Ligase; Motility/polarity/chemotaxis; Apoptosis; EC 6.3.2.19; Cell development/differentiation; Ubiquitin conjugating system; Ubiquitin ligase
Chromosomal Location of Human Ortholog: 16q12.1
Cellular Component: early endosome; cytoplasm; plasma membrane; beta-catenin destruction complex; nucleus; cytosol
Molecular Function: protein C-terminus binding; protein binding; zinc ion binding; ubiquitin-protein ligase activity; ligase activity
Biological Process: ubiquitin-dependent protein catabolic process; proteasomal ubiquitin-dependent protein catabolic process; nervous system development; axon guidance; anatomical structure morphogenesis; neuron apoptosis; protein destabilization; apoptosis; positive regulation of apoptosis; protein ubiquitination during ubiquitin-dependent protein catabolic process; spermatogenesis; protein catabolic process; cell cycle
Show more Protein type: EC 6.3.2.-; Ligase; Motility/polarity/chemotaxis; Apoptosis; EC 6.3.2.19; Cell development/differentiation; Ubiquitin conjugating system; Ubiquitin ligase
Chromosomal Location of Human Ortholog: 16q12.1
Cellular Component: early endosome; cytoplasm; plasma membrane; beta-catenin destruction complex; nucleus; cytosol
Molecular Function: protein C-terminus binding; protein binding; zinc ion binding; ubiquitin-protein ligase activity; ligase activity
Biological Process: ubiquitin-dependent protein catabolic process; proteasomal ubiquitin-dependent protein catabolic process; nervous system development; axon guidance; anatomical structure morphogenesis; neuron apoptosis; protein destabilization; apoptosis; positive regulation of apoptosis; protein ubiquitination during ubiquitin-dependent protein catabolic process; spermatogenesis; protein catabolic process; cell cycle
Research Articles on SIAH1/2
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with anti-SIAH1/2 antibody
| Reference Product | PubMed Publications |
|---|---|
| CACYBP antibody | >4 publications with SIAH1/2 and CACYBP |
| AFF1 antibody | >3 publications with SIAH1/2 and AFF1 |
| PEG3 antibody | >2 publications with SIAH1/2 and PEG3 |
| AXIN1 antibody | >1 publications with SIAH1/2 and AXIN1 |
| DCC antibody | >1 publications with SIAH1/2 and DCC |
Pathways associated with anti-SIAH1/2 antibody
| Products by Pathway | Pathway Diagram |
|---|---|
| Axon Guidance Pathway antibodies | Axon Guidance Pathway Diagram |
| Developmental Biology Pathway antibodies | Developmental Biology Pathway Diagram |
| Netrin-1 Signaling Pathway antibodies | Netrin-1 Signaling Pathway Diagram |
| Parkin-Ubiquitin Proteasomal System Pathway antibodies | Parkin-Ubiquitin Proteasomal System Pathway Diagram |
| Ubiquitin Mediated Proteolysis Pathway antibodies | Ubiquitin Mediated Proteolysis Pathway Diagram |
| Ubiquitin Mediated Proteolysis Pathway antibodies | Ubiquitin Mediated Proteolysis Pathway Diagram |
| Wnt Signaling Pathway antibodies | Wnt Signaling Pathway Diagram |
| Wnt Signaling Pathway antibodies | Wnt Signaling Pathway Diagram |
| P53 Signaling Pathway antibodies | P53 Signaling Pathway Diagram |
| P53 Signaling Pathway antibodies | P53 Signaling Pathway Diagram |
Diseases associated with anti-SIAH1/2 antibody
| Disease Name | Pubmed Publications |
|---|---|
| Central Nervous System Diseases Antibodies | >9 publications with SIAH1/2 and Central Nervous System Diseases |
| Nervous System Diseases Antibodies | >9 publications with SIAH1/2 and Nervous System Diseases |
| Brain Diseases Antibodies | >8 publications with SIAH1/2 and Brain Diseases |
| Liver Diseases Antibodies | >6 publications with SIAH1/2 and Liver Diseases |
| Breast Neoplasms Antibodies | >6 publications with SIAH1/2 and Breast Neoplasms |
| Cell Transformation, Neoplastic Antibodies | >6 publications with SIAH1/2 and Cell Transformation, Neoplastic |
| Adenocarcinoma Antibodies | >5 publications with SIAH1/2 and Adenocarcinoma |
| Movement Disorders Antibodies | >3 publications with SIAH1/2 and Movement Disorders |
| Nerve Degeneration Antibodies | >3 publications with SIAH1/2 and Nerve Degeneration |
| Weight Loss Antibodies | >2 publications with SIAH1/2 and Weight Loss |
Organs/Tissues associated with anti-SIAH1/2 antibody
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Brain Antibodies | >8 publications with SIAH1/2 and Brain |
| Liver Antibodies | >6 publications with SIAH1/2 and Liver |
| Lung Antibodies | >5 publications with SIAH1/2 and Lung |
| Kidney Antibodies | >4 publications with SIAH1/2 and Kidney |
| Vascular Antibodies | >4 publications with SIAH1/2 and Vascular |
| Blood Antibodies | >4 publications with SIAH1/2 and Blood |
| Muscle Antibodies | >3 publications with SIAH1/2 and Muscle |
| Embryonic Tissue Antibodies | >2 publications with SIAH1/2 and Embryonic Tissue |
| Thymus Antibodies | >2 publications with SIAH1/2 and Thymus |
| Heart Antibodies | >2 publications with SIAH1/2 and Heart |


